May 08,2024

Trinity Biotech Welcomes Avinash Kale as Continuous Glucose Monitor Programme Director to Advance Innovation and Development

Trinity Biotech plc, a biotechnology company focusing on human diagnostics and diabetes management solutions, has appointed Avinash Kale as Continuous Glucose Monitor (CGM) Programme Director. Kale's role is crucial in advancing the company's recently acquired CGM technology and driving its innovation for global market access. Trinity aims to introduce intelligent wearable biosensors, including CGMs, worldwide to address the needs of millions impacted by diabetes. Kale, a seasoned leader in MedTech R&D and innovation, brings extensive global industry experience to Trinity, having worked with Fortune 500+ firms and start-ups. His appointment underscores Trinity's commitment to developing state-of-the-art CGM solutions accessible to patients globally.

View Analyst & Ambassador Comments
Go to original news
May 07,2024

DarioHealth to Report First Quarter 2024 Results on Wednesday, May 15th

DarioHealth announced today that it will release its financial results for the 1st quarter ended March 31st, 2024, on Wednesday, May 15th, 2024, before the market opens and will host a conference call and webcast at 8:30 am Eastern Time. Erez Raphael, Chief Executive Officer and Rick Anderson, President, will host the call.

View Analyst & Ambassador Comments
Go to original news
May 02,2024

Tandem Diabetes Care Announces First Quarter 2024 Financial Results and Updates Full Year 2024 Financial Guidance

Tandem Diabetes Care reported its financial results for the quarter ended March 31, 2024 and increased sales guidance for the year ending December 31, 2024. The Company announced that its worldwide pump shipments increased 9 percent to approximately 25,000 pumps from 23,000 pumps, and its worldwide GAAP sales increased 13 percent to $191.7 million while its worldwide non-GAAP sales increased 12 percent to $192.8 million. 

View Analyst & Ambassador Comments
Go to original news
May 02,2024

Intuity Medical’s POGO Automatic®, the First and Only FDA-Cleared Automatic Blood Glucose Monitor, Now Covered by Medicare Part B

Intuity Medical's POGO Automatic Blood Glucose Monitoring system, designed to simplify diabetes management, is now covered by Medicare Part B. This expansion of coverage benefits the 16.5 million seniors aged 65 and up living with diabetes. POGO Automatic aims to improve testing compliance, particularly among seniors facing challenges with traditional meters. The system addresses the need for simpler blood glucose testing methods, with new coverage codes allowing Medicare beneficiaries to access this technology. Intuity Medical is collaborating with retail pharmacies to ensure timely access for patients.

PRODUCT

#reimbursement

#bgm

View Analyst & Ambassador Comments
Go to original news
May 02,2024

GLUCOTRACK ANNOUNCES ABSTRACTS ACCEPTED FOR POSTER PRESENTATION AT 84TH SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION

Glucotrack, Inc., a medical device company focusing on innovations for diabetes, has had two abstracts accepted for poster presentation at the American Diabetes Association's Scientific Sessions in June 2024. The posters will discuss preclinical animal studies and sensor longevity simulation modeling for their Continuous Blood Glucose Monitor (CBGM). Presentation details and poster content will be available on Glucotrack's website after the conference.

CONFERENCES

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 29,2024

Tandem Diabetes Care Announces Upcoming Conference Presentations

Tandem Diabetes Care announced that management will present a company update at the following investor conferences: BofA Securities Health Care Conference 2024 on Wednesday, May 15, 2024 at 1:00pm Eastern Time (10:00am Pacific Time), and Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024 at 12:20pm Eastern Time (9:20am Pacific Time).

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Apr 30,2024

Eversense® CGM System Receives iCGM Designation by the US FDA

Senseonics Holdings and Ascensia Diabetes Care announced that the Eversense continuous glucose monitoring (CGM) system has received integrated CGM (iCGM) designation from the US FDA. This marks the first fully implantable device in this category, authorized for marketing through the FDA's De Novo pathway. The iCGM status allows Eversense to integrate with compatible medical devices, such as insulin pumps, particularly for automated insulin delivery (AID) systems. The companies intend to pursue partnerships with various pump manufacturers to offer users of diabetes devices a new interoperable CGM option suitable for AID systems.

REGULATORY FDA

#closed loop

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 25,2024

Dario Publishes New Peer-Reviewed Study that Deepens the Body of Evidence that Managing Cardiometabolic Conditions in One Integrated Platform Improves Clinical Outcomes

DarioHealth unveiled new research published in the Journal of Internet Medicine, indicating a notable reduction in blood glucose levels among users managing weight alongside diabetes with the Dario platform. This retrospective study of 1,932 Dario members over a year revealed significant improvements in blood glucose levels and BMI for those utilizing Dario's weight monitoring feature compared to those who did not. The study underscores the importance of integrated solutions for managing Type 2 diabetes and obesity, offering promising implications for enhancing patient outcomes. The research was conducted in collaboration with the School of Public Health at the University of Haifa.

CLINICAL STUDY

#dtx

#coaching

View Analyst & Ambassador Comments
Go to original news
Apr 23,2024

Roche and VinCense to augment access to diabetes care in Tamil Nadu

Roche has forged a Memorandum of Understanding (MoU) with VinCense, a digital health monitoring service by MedIoTek Health Systems, to implement three programs in Madurai district, Tamil Nadu. These programs include screening 100,000 individuals over two years for diabetes, hypertension, and obesity, managing uncontrolled diabetes mellitus, and addressing tuberculosis-diabetes mellitus co-morbidity. The partnership aims to utilize integrated digital health solutions for early detection, intervention, and continuous care. Following a successful pilot phase from December 2022 to September 2023, where 67,370 individuals were screened, the initiative seeks to set new standards for accessible and technology-driven healthcare. The collaboration integrates Roche's expertise in public healthcare programs with VinCense's technology, enabling comprehensive health data recording and personalized dashboards for improved health insights.

COLLABORATION PARTNERSHIP

#connected device

#virtual care

View Analyst & Ambassador Comments
Go to original news
Apr 15,2024

DexCom, MD Revolution Unite to Boost Diabetes Management

DexCom and MD Revolution recently announced their partnership, where Dexcom is likely to integrate its industry-leading continuous glucose monitoring (CGM) systems with MD Revolution’s remote care management.  As a result of the partnership, patients' glucose monitoring data can now be made available to clinicians through MD Revolution’s care management platform, which is likely to empower clinicians to make informed decisions and provide better patient care. MD Revolution offers a remote care management platform that seamlessly integrates with an ecosystem of EHRs, data partners, and devices to power comprehensive remote care for large practices, health systems and healthcare organizations. 

COLLABORATION PARTNERSHIP

#connected device

#cgm

#rpm

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES